Viridian Therapeutics, Inc. (FRA:1S1)
Germany
· Delayed Price · Currency is EUR 27.45
+0.95 (3.58%)
At close: Dec 5, 2025
Viridian Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 70.79 | 0.3 | 0.31 | 1.77 | 2.96 | 1.05 | Upgrade
|
| Revenue Growth (YoY) | 23340.07% | -3.82% | -82.28% | -40.20% | 182.19% | -76.46% | Upgrade
|
| Cost of Revenue | 318.18 | 238.25 | 159.77 | 100.89 | 56.89 | 28.3 | Upgrade
|
| Gross Profit | -247.39 | -237.95 | -159.45 | -99.12 | -53.92 | -27.25 | Upgrade
|
| Selling, General & Admin | 77.23 | 61.08 | 95 | 35.18 | 25.81 | 13.27 | Upgrade
|
| Operating Expenses | 77.23 | 61.08 | 95 | 35.18 | 25.81 | 13.27 | Upgrade
|
| Operating Income | -324.62 | -299.04 | -254.45 | -134.3 | -79.73 | -40.52 | Upgrade
|
| Interest Expense | -3.03 | -3.05 | -1.85 | -0.49 | -0 | -0.51 | Upgrade
|
| Interest & Investment Income | 28.66 | 32.13 | 18.56 | 4.92 | 0.32 | 0.17 | Upgrade
|
| EBT Excluding Unusual Items | -298.47 | -269.95 | -237.73 | -129.87 | -79.41 | -40.85 | Upgrade
|
| Other Unusual Items | -3.5 | - | - | - | - | - | Upgrade
|
| Pretax Income | -301.97 | -269.95 | -237.73 | -129.87 | -79.41 | -110.72 | Upgrade
|
| Net Income | -301.97 | -269.95 | -237.73 | -129.87 | -79.41 | -110.72 | Upgrade
|
| Preferred Dividends & Other Adjustments | -56.65 | -61.39 | -62.73 | -42.83 | - | - | Upgrade
|
| Net Income to Common | -245.32 | -208.56 | -175.01 | -87.04 | -79.41 | -110.72 | Upgrade
|
| Shares Outstanding (Basic) | 81 | 68 | 45 | 32 | 12 | 4 | Upgrade
|
| Shares Outstanding (Diluted) | 81 | 68 | 45 | 32 | 12 | 4 | Upgrade
|
| Shares Change (YoY) | 34.66% | 51.68% | 39.48% | 169.22% | 235.07% | 70.27% | Upgrade
|
| EPS (Basic) | -3.02 | -3.07 | -3.91 | -2.71 | -6.66 | -31.13 | Upgrade
|
| EPS (Diluted) | -3.02 | -3.07 | -3.91 | -2.71 | -6.66 | -31.13 | Upgrade
|
| Free Cash Flow | -326.34 | -232.83 | -185.07 | -94.64 | -54.92 | -29.82 | Upgrade
|
| Free Cash Flow Per Share | -4.02 | -3.43 | -4.13 | -2.95 | -4.61 | -8.38 | Upgrade
|
| Operating Margin | -458.57% | -99018.21% | -81035.03% | -7579.23% | -2690.79% | -3858.95% | Upgrade
|
| Profit Margin | -346.55% | -69059.60% | -55734.71% | -4912.13% | -2680.15% | -10544.29% | Upgrade
|
| Free Cash Flow Margin | -461.00% | -77096.03% | -58938.85% | -5340.58% | -1853.49% | -2840.10% | Upgrade
|
| EBITDA | -324.16 | -298.5 | -253.93 | -134.05 | -79.61 | -40.28 | Upgrade
|
| D&A For EBITDA | 0.46 | 0.54 | 0.52 | 0.26 | 0.12 | 0.24 | Upgrade
|
| EBIT | -324.62 | -299.04 | -254.45 | -134.3 | -79.73 | -40.52 | Upgrade
|
| Revenue as Reported | 70.49 | - | - | - | - | 1.05 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.